Healthcare / Drug Manufacturers - GeneralShenzhen
$4.13
+0.09 (+2.23%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 16%
FCF escenarios
weak_data · normalized FCF $22.1M · quality 36.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
25/100
D
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$2.1B
P/E
82.6x
↑EV/EBITDA
32.5x
↑ROE
4.2%
↑Gross Margin
59.9%
↑Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-16.5%
FCF CAGR
—
FCF margin
-26.3%
FCF / Net income
-3.31x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $383.8M · net income $30.5M · FCF $-100.9M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $383.8M | $383.8M | $376.2M | $533.2M | $659.2M |
| Net Income | $30.5M | $30.5M | $20.6M | $34.3M | $43.9M |
| EBITDA | $59.4M | $59.4M | $44.7M | $63.6M | $77.4M |
| EPS | 0.06 | 0.06 | 0.04 | 0.07 | 0.09 |
| Gross Margin | 59.9% | 59.9% | 59.9% | 65.2% | 65.3% |
| Operating Margin | 11.6% | 11.6% | 7.1% | 7.0% | 8.3% |
| Net Margin | 7.9% | 7.9% | 5.5% | 6.4% | 6.7% |
| Balance Sheet | |||||
| Current Ratio | 15.15 | 15.15 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-100.9M | $-100.9M | $22.1M | $93.4M | $24.4M |
| Returns | |||||
| ROE | 4.2% | 4.2% | 2.7% | 4.5% | 6.0% |
| Valuation | |||||
| P/E | 82.60 | 82.60 | 169.21 | 106.66 | 75.75 |
| EV/EBITDA | 32.47 | 32.47 | 70.47 | 55.47 | 40.60 |
| P/B | 2.92 | 2.92 | 4.60 | 4.80 | 4.57 |
| Growth & Yield | |||||
| Revenue Growth | 2.0% | 2.0% | -29.5% | -19.1% | — |
| EPS Growth | 48.0% | 48.0% | -39.9% | -21.9% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
82.7%
EPS terminal req.
$0.37
Spread vs growth
-34.7%
5Y implied EPS CAGR
49.1%
EPS terminal req.
$0.44
Spread vs growth
-1.1%
10Y implied EPS CAGR
28.1%
EPS terminal req.
$0.71
Spread vs growth
19.9%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-40.4%
Start / end P/E
170.7x → 68.7x
EPS bridge
0.04 → 0.06
Residual
-28.7%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.